Augmentation of autoantibodies by Helicobacter pylori in Parkinson's disease patients may be linked to greater severity

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Suwarnalata, Gunasekaran ^a   Tan, Ai Huey ^a   Isa, Hidayah ^a   Gudimella, Ranganath ^a   Anwar, Arif ^a   Loke, Mun Fai ^a   Mahadeva, Sanjiv ^a   Lim, Shen Yang ^a   Vadivelu, Jamuna ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BOVINE SERUM ALBUMIN; CYANINE DYE 3; EUKARYOTIC TRANSLATION INITIATION FACTOR 4A3; IMMUNOGLOBULIN G; INITIATION FACTOR; MEMBRANE PROTEIN; NUCLEAR FACTOR I SUBTYPE A; PLATELET DERIVED GROWTH FACTOR B; UNCLASSIFIED DRUG; INITIATION FACTOR 4A; NFIA PROTEIN, HUMAN; NUCLEAR FACTOR I;

AGED; ANTIBODY DETECTION; ARTICLE; BACTERIUM IDENTIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MOLECULAR DYNAMICS; NONHUMAN; PARKINSON DISEASE; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUALITY CONTROL; UPREGULATION; BLOOD; COMPLICATION; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED;

AGED; AUTOANTIBODIES; EUKARYOTIC INITIATION FACTOR-4A; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; NFI TRANSCRIPTION FACTORS; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-SIS;

EID: 84964645592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153725     Document Type: Article

References (50)

1. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci. 2014; 59:1698-709. doi: 10.1007/s10620-014-3063-0 PMID: 24563236
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347:1175-86. PMID: 12374879
3. Bauer B, Meyer TF. The human gastric pathogen Helicobacter pylori and its association with gastric cancer and ulcer disease. Ulcers 2011; 2011:340157.
4. Baudron CR, Franceschi F, Salles N, Gasbarrini A. Extragastric diseases and Helicobacter pylori. Helicobacter. 2013; 18:44-51. doi: 10.1111/hel.12077 PMID: 24011245
5. Sakagami T, Dixon M, O'Rourke J, Howlett R, Alderuccio F, Vella J, et al. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut. 1996; 39:639-48. PMID: 9026476
6. Toh BH. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev. 2014; 13:459-62. doi: 10.1016/j.autrev.2014.01.048 PMID: 24424193
7. Ayada K, Yokota K, Hirai K, Fujimoto K, Kobayashi K, Ogawa H, et al. Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis. Lupus. 2009; 18:1154-68. doi: 10.1177/0961203309106600 PMID: 19880562
8. Ram M, Barzilai O, Shapira Y, Anaya JM, Tincani A, Stojanovich L, et al. Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med. 2013; 51:1075-82. doi: 10.1515/cclm- 2012-0477 PMID: 23079514
9. Strang RR.The association of gastro-duodenal ulceration and Parkinson's disease. The Medical Journal of Australia. 1965; 1:842-3. PMID: 14313339
10. Strang RR. The occurrence of peptic ulceration in patients with parkinsonism. Acta Neurologica Scandinavica. 1966; 42:124-7.
11. Dobbs SM, Dobbs RJ, Weller C, Charlett A. Link between Helicobacter pylori infection and idiopathic parkinsonism. Med Hypotheses. 2000; 55:93-8. PMID: 10904422
12. Dobbs RJ, Dobbs SM, Weller C, Charlett A, Bjarnason IT, Curry A, et al. Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter. 2008; 13:309-22. doi: 10.1111/j.1523-5378. 2008.00622.x PMID: 19250506
13. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol. 2012; 19:864-9. doi: 10.1111/j.1468-1331.2011. 03643.x PMID: 22248366
14. Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, et al. Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism Relat Disord. 2015; 21:221-5. doi: 10.1016/j.parkreldis.2014.12.009 PMID: 25560322
15. Dobbs RJ, Charlett A, Dobbs SM, Weller C, A Ibrahim MA, Iguodala O, et al. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinalbacterial overgrowth. A surveillance study. Gut Pathog. 2012; 4:12. doi: 10.1186/1757-4749-4-12 PMID: 23083400
16. Dobbs RJ, Charlett A, Dobbs SM, Weller C, Iguodala O, Smee C, et al. Towards defining a rigidity-associated pathogenic pathway in idiopathic parkinsonism. Neurodegener Dis. 2012; 10:183-6. doi: 10.1159/000332807 PMID: 22205039
17. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006; 66:1824-9. PMID: 16801644
18. Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, et al. Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev. 2011; 11:CD008453. doi: 10.1002/14651858. CD008453.pub2 PMID: 22071847
19. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, et al. Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter. 2010 Aug; 15(4):279-94. doi: 10.1111/j.1523-5378.2010.00768.x PMID: 20633189
20. Dobbs SM, Charlett A, Dobbs RJ, Weller C, Iguodala O, Smee C, et al. Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. Helicobacter. 2013; 18:187-96. doi: 10.1111/hel.12035 PMID: 23336966
21. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Augustin A, Taylor D, et al. Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. J Neurovirol. 2016; 22:22-32. doi: 10.1007/s13365-015-0357-8 PMID: 26092111
22. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003; 110:517-36.
23. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord. 2008; 23:1065-75. doi: 10.1002/mds.22051 PMID: 18442139
24. Deretzi G, Kountouras J, Polyzos SA, Zavos C, Giartza-Taxidou E, Gavalas E, et al. Gastrointestinal immune system and brain dialogue implicated in neuroinflammatory and neurodegenerative diseases. Curr Mol Med. 2011; 11:696-707. PMID: 21902649
25. Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Persepect. 2003; 111:1065-73.
26. Arai H, Furuya T, Mizuno Y, Mochizuki H. Inflammation and infection in Parkinson's disease. Histol Histopathol. 2006; 21:673-8. PMID: 16528677
27. Godoy MCP, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain. 2008; 131:1880-94. doi: 10.1093/brain/awn101 PMID: 18504291
28. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013; 62:132-44. doi: 10.1016/j.freeradbiomed.2013.01.018 PMID: 23380027
29. Boutell JM, Hart DJ, Goder BL, Kozlowski RZ, Blackburn JM. Functional protein microarrays for parallel characterization of p53 mutants. Proteomics. 2004; 4:1950-8. PMID: 15221755
30. Robinson WH, Steinman L, Utz PJ. Protein arrays for autoantibody profiling and fine-specificity mapping. Proteomics. 2003; 3:2077-84. PMID: 14595805
31. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004; 19:1020-8. PMID: 15372591
32. Everhart JE, Kruszon-Moran D, Perez-Perez G. Reliability of Helicobacter pylori and CagA serological assays. Clin Diagn Lab Immunol. 2002; 9:412-6. PMID: 11874887
33. Contreras M, Pujol FH, Pérez-Pérez GI, Marini E, Michelangeli FA, Ponce L, et al. Helicobacter pylori seroprevalence in Amerindians from isolated locations. Am J Trop Med Hyg. 2008; 78:574-6. PMID: 18385351
34. Romero-Gallo J, Pérez-Pérez GI, Novick RP, Kamath P, Norbu T, Blaser MJ. Responses of endoscopy patients in Ladakh, India, to Helicobacter pylori whole-cell and CagA antigens. Clin Diagn Lab Immunol. 2002; 9:1313-7. PMID: 12414766
35. Negrini R, Lisato L, Zanella I, Cavazzini L, Gullini S, Villanacci V, et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology. 1991; 101:437-45. PMID: 2065920
36. Negrini R, Savio A, Graffeo M, Rolfi F, Ghielmi S. Autoantibodies and gastric Helicobacter pylori infection: does autoimmunity affect progression to atrophic gastritis? Eur J Gastroenterol Hepatol. 1993; 5 (Suppl. 2):S27-9.
37. Negrini R, Zanella I, Savio A, Poiesi C, Verardi R, Ghielmi S, et al. Serodiagnosis of Helicobacter pylori-associated gastritis with a monoclonal antibody competitive enzyme-linked immunosorbent assay. Scand J Gastroenterol. 1992; 27:599-605. PMID: 1641587
38. Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004; 124:91-6. PMID: 14675413
39. Weller C, Charlett A, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, Bjarnason IT. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter. 2005; 10:288-97. PMID: 16104944
40. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, et al. Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter. 2010; 15:279-94. doi: 10.1111/j.1523-5378.2010.00768.x PMID: 20633189
41. Supajatura V, Ushio H, Wada A, Yahiro K, Okumura K, Ogawa H, et al. Cutting edge: VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration and production of proinflammatory cytokines. J Immunol. 2002; 168:2603-7. PMID: 11884423
42. Zheng S, Eacker SM, Hong SJ, Gronostajski RM, Dawson TM, Dawson VL. NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J Clin Invest. 2010; 120:2446-56. doi: 10.1172/JCI33144 PMID: 20516644
43. Nikkhah G, Odin P, Smits A, Tingström A, Othberg A, Brundin P,et al. Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp Brain Res. 1993; 92:516-23. PMID: 8095907
44. Othberg A, Odin P, Ballagi A, Ahgren A, Funa K, Lindvail O. Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in vitro. Exp Brain Res. 1995; 105:111-22. PMID: 7589308
45. Pietz K, Odin P, Faun K, Lindvall O. Protective effect of platelet-derived growth factor against 6-hydroxydopamine- induced lesion of rat dopaminergic neurons in culture. Neurosci Lett. 1996; 204:101-4. PMID: 8929988
46. Funa K, Yamada N, Brodin G, Pietz K, Ahgren A, Wictorin K, et al. Enhanced synthesis of plateletderived growth factor following injury induced by 6-hydroxydopamine in rat brain. Neuroscience. 1996; 74:825-33. PMID: 8884778
47. Zachrisson O, Zhao M, Andersson A, Dannaeus K, Häggblad J, Isacson R, et al. Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinsons Dis. 2011; 1:49-63. doi: 10.3233/JPD-2011-0003 PMID: 23939256
48. Paul G, Zachrisson O, Varrone A, Almqvist P, Jerling M, Lind G, et al. Safety and tolerance of intracerebroventricular PDGF-BB in Parkinson's disease patients. J Clin Invest. 2015; 125:1339-46. doi: 10.1172/JCI79635 PMID: 25689258
49. Barker-Haliski ML, Pastuzyn ED, Keefe KA. Expression of the core exon-junction complex factor eIF4A3 is increased during spatial exploration and striatally-mediated learning. Neuroscience. 2012; 226:51-61. doi: 10.1016/j.neuroscience.2012.09.003 PMID: 22982623
50. Solari N, Bonito-Oliva A, Fisone G, Brambilla R. Understanding cognitive deficits in Parkinson's disease: lessons from preclinical animal models. Learn Mem. 2013; 20:592-600. doi: 10.1101/lm. 032029.113 PMID: 24049188